CO154 Ramucirumab+Docetaxel Post Immune Checkpoint Inhibitors (ICIS) and Platinum-Based Chemotherapy (CHEMO) in Advanced or Metastatic Non-Small Cell Lung Cancer (ANSCLC): Learnings from the Treat-Lung Observational Study ← Characteristics and Clinical Outcomes of Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma Who Received At Least 3 Lines of TherapiesLong-Term Real-World Treatment Patterns Among Patients With Diabetic Macular Edema Initiating Anti-VEGF: 6-Year Follow-Up Using the IRIS® Registry →
